As delineated above, the feasibility of MST1 and AMPK as therapeutic targets has been demonstrated in pancreatic β cells and diabetic mouse models, and thus the development of MST1 inhibitors and AMPK activators could therefore provide a promising approach as pancreas protective and metabolism adjusting agents for the management of diabetes mellitus. The gene discussed is MST1; the disease is diabetes mellitus.